BioCentury | Dec 30, 2016
Emerging Company Profile

Mining for substitutions

Riptide Bioscience Inc. has mined the sequences and structures of failed first-generation peptide therapeutics to engineer a new class of host defense peptides with amino acid substitutions that could make its candidates more effective in...
BC Week In Review | Dec 24, 2012
Clinical News

DPK-060: Phase II data

Top-line data from a double-blind, placebo-controlled, Swedish Phase II trial in 69 patients with acute external otitis caused by bacterial or fungal pathogens showed that thrice-daily DPK-060 2% ear drops for 7-10 days was safe...
BC Week In Review | Jan 23, 2012
Clinical News

DPK-060: Phase II started

Pergamum began a double-blind, placebo-controlled, Swedish Phase II trial to evaluate thrice-daily DPK-060 2% ear drops for 7-10 days in about 70 patients with acute external otitis caused by bacterial or fungal pathogens. Pergamum AB...
BC Week In Review | Dec 7, 2009
Clinical News

DPK-060: Phase I/IIa data

Data from the double-blind, placebo-controlled portion of a Phase I/IIa trial in 41 patients showed that twice-daily DPK-060 met the primary endpoint of significantly reducing microbial density in eczematous lesions vs. placebo at day 14...
BC Week In Review | Sep 14, 2009
Company News

Karolinska Development dermatology, musculoskeletal news

Karolinska combined its portfolio companies DermaGen AB (Lund, Sweden), Lipopeptide AB (Stockholm, Sweden) and PharmaSurgics AB (Gothenburg, Sweden), into newco Pergamum AB . Karolinska also transferred its minority holdings in Omnio Healer AB (Umea, Sweden) and...
Items per page:
1 - 5 of 5